These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
454 related articles for article (PubMed ID: 22999748)
1. Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization. Prajapati HJ; Rafi S; El-Rayes BF; Kauh JS; Kooby DA; Kim HS J Vasc Interv Radiol; 2012 Oct; 23(10):1286-93.e1. PubMed ID: 22999748 [TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519 [TBL] [Abstract][Full Text] [Related]
3. Safety and feasibility of same-day discharge of patients with hepatocellular carcinoma treated with transarterial chemoembolization with drug-eluting beads in a liver transplantation program. Nasser F; Cavalcante RN; Galastri FL; de Rezende MB; Felga GG; Travassos FB; De Fina B; Affonso BB J Vasc Interv Radiol; 2014 Jul; 25(7):1012-7. PubMed ID: 24704346 [TBL] [Abstract][Full Text] [Related]
4. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737 [TBL] [Abstract][Full Text] [Related]
5. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS J Surg Oncol; 2010 May; 101(6):476-80. PubMed ID: 20213741 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles. Padia SA; Shivaram G; Bastawrous S; Bhargava P; Vo NJ; Vaidya S; Valji K; Harris WP; Hippe DS; Kogut MJ J Vasc Interv Radiol; 2013 Mar; 24(3):301-6. PubMed ID: 23380737 [TBL] [Abstract][Full Text] [Related]
7. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up. Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569 [TBL] [Abstract][Full Text] [Related]
8. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma. Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001 [TBL] [Abstract][Full Text] [Related]
9. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization. Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436 [TBL] [Abstract][Full Text] [Related]
10. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. Sacco R; Bargellini I; Bertini M; Bozzi E; Romano A; Petruzzi P; Tumino E; Ginanni B; Federici G; Cioni R; Metrangolo S; Bertoni M; Bresci G; Parisi G; Altomare E; Capria A; Bartolozzi C J Vasc Interv Radiol; 2011 Nov; 22(11):1545-52. PubMed ID: 21849247 [TBL] [Abstract][Full Text] [Related]
11. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849 [TBL] [Abstract][Full Text] [Related]
12. Safety profile of sequential transcatheter chemoembolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients. Malagari K; Pomoni M; Spyridopoulos TN; Moschouris H; Kelekis A; Dourakis S; Alexopoulou E; Koskinas J; Angelopoulos M; Kornezos J; Pomoni A; Tandeles S; Marinis A; Rizos S; Kelekis D Cardiovasc Intervent Radiol; 2011 Aug; 34(4):774-85. PubMed ID: 21184228 [TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma. Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191 [TBL] [Abstract][Full Text] [Related]
14. Korean Multicenter Registry of Transcatheter Arterial Chemoembolization with Drug-Eluting Embolic Agents for Nodular Hepatocellular Carcinomas: Six-Month Outcome Analysis. Lee M; Chung JW; Lee KH; Won JY; Chun HJ; Lee HC; Kim JH; Lee IJ; Hur S; Kim HC; Kim YJ; Kim GM; Joo SM; Oh JS J Vasc Interv Radiol; 2017 Apr; 28(4):502-512. PubMed ID: 27856136 [TBL] [Abstract][Full Text] [Related]
15. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Song MJ; Park CH; Kim JD; Kim HY; Bae SH; Choi JY; Yoon SK; Chun HJ; Choi BG; Lee HG Eur J Gastroenterol Hepatol; 2011 Jun; 23(6):521-7. PubMed ID: 21537127 [TBL] [Abstract][Full Text] [Related]
16. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization. Sadick M; Haas S; Loehr M; Elshwi M; Singer MV; Brade J; Schoenberg SO; Diehl SJ Onkologie; 2010; 33(1-2):31-7. PubMed ID: 20164659 [TBL] [Abstract][Full Text] [Related]
17. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study. Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418 [TBL] [Abstract][Full Text] [Related]
18. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma]. Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802 [TBL] [Abstract][Full Text] [Related]
19. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027 [TBL] [Abstract][Full Text] [Related]
20. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]